Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Indigenous Canadians confront prescription opioid misuse.

Webster PC.

Lancet. 2013 Apr 27;381(9876):1447-8. No abstract available.

PMID:
23630985
2.

Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.

Nielsen S, Hillhouse M, Mooney L, Ang A, Ling W.

J Subst Abuse Treat. 2015 Jan;48(1):70-6. doi: 10.1016/j.jsat.2014.06.006. Epub 2014 Jun 28.

3.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
4.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
5.

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Alho H, Sinclair D, Vuori E, Holopainen A.

Drug Alcohol Depend. 2007 Apr 17;88(1):75-8. Epub 2006 Oct 19.

PMID:
17055191
6.

In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.

[No authors listed]

Med Lett Drugs Ther. 2013 Oct 14;55(1427):83. No abstract available.

PMID:
24129113
7.
8.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
9.

Responding to the prescription opioid epidemic: practical information for pediatricians.

Wunsch MJ, Gonzalez PK.

Adolesc Med State Art Rev. 2014 Apr;25(1):104-12. Review. No abstract available.

PMID:
25022189
10.

Non-medical prescription opioid use among youth: Gaining perspective from decades of previous drug use epidemics.

Cheng T, DeBeck K, Small W.

Int J Drug Policy. 2016 Jan;27:184-5. doi: 10.1016/j.drugpo.2015.06.004. Epub 2015 Jun 29. No abstract available.

PMID:
26205675
11.

Buprenorphine-naloxone treatment of prescription opioid abuse: does past performance predict future results?

Langleben DD.

J Clin Psychiatry. 2015 Feb;76(2):195-7. doi: 10.4088/JCP.14com09617. No abstract available.

12.

Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.

Curcio F, Franco T, Topa M, Baldassarre C; Gruppo Responsabili UO Sert T.

Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):871-4.

PMID:
21845796
13.

Canada's prescription opioid epidemic grows despite tamperproof pills.

Dyer O.

BMJ. 2015 Sep 3;351:h4725. doi: 10.1136/bmj.h4725. No abstract available.

PMID:
26338104
14.

Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.

Moratti E, Kashanpour H, Lombardelli T, Maisto M.

Clin Drug Investig. 2010;30 Suppl 1:3-11. doi: 10.2165/11536020-000000000-00000.

PMID:
20450240
15.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
16.

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L.

Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004. Epub 2010 Nov 27.

PMID:
21112758
17.

Topical review on the abuse and misuse potential of tramadol and tilidine in Germany.

Radbruch L, Glaeske G, Grond S, Münchberg F, Scherbaum N, Storz E, Tholen K, Zagermann-Muncke P, Zieglgänsberger W, Hoffmann-Menzel H, Greve H, Cremer-Schaeffer P.

Subst Abus. 2013;34(3):313-20. doi: 10.1080/08897077.2012.735216. Review.

PMID:
23844964
18.

A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone).

Welsh C, Sherman SG, Tobin KE.

Addiction. 2008 Jul;103(7):1226-8. doi: 10.1111/j.1360-0443.2008.02244.x.

PMID:
18554353
19.

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.

Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):44-9. doi: 10.1016/j.drugalcdep.2010.03.014. Epub 2010 May 15.

PMID:
20478668
20.

Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.

Clay E, Khemiri A, Zah V, Aballéa S, Ruby J, Asche CV.

J Med Econ. 2014 Sep;17(9):626-36. doi: 10.3111/13696998.2014.925463. Epub 2014 Jun 6.

PMID:
24841329

Supplemental Content

Support Center